Why Pfizer lurking in the clinical trial shadows i

Why Pfizer lurking in the clinical trial shadows is so important . . .

An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix ( OTCBB : CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker.

A portion of the article:

“Beth Israel and Pfizer will be able to watch Kevetrin through the dual lenses of both the Pfizer straddle clinicals, as well as the FDA stage 1 at Dana Farber. Remember, Pfizer is the 180 billion cap company with a 15 billion dollar checkbook. A buyout or joint venture twice the size of Celgene’s $925 million payment for Avail is pocket change for Pfizer. During or very shortly after Kevetrin’s safety profile is established, data may very well be generated that would indicate that Kevetrin’s therapeutic platform could have much broader and more significant oncolytic ability than Avail’s AVL-292, which is focused on hemoglobic cancers. If indeed that’s the case, approximately 16 to 18 months from the initiation of FDA stage 1, Kevetrin might be shared with or owned by a large multinational pharmaceutical company.”

Interested parties are encouraged to read the complete article at http://seekingalpha.com/article/802771-pfizer-eyes-kevetrin .